A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

NCT06511570 | Completed Phase 1 FDA Drug

• 1 other identifier: ACU193-102
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Conditions

Alzheimer Disease

Outcome Measures

Primary Outcomes (10)

• Estimate blood levels of sabirnetug (ACU193)

  Cmax (Maximum concentration, determined directly from individual concentration-time data)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate time to reach maximum blood levels of sabirnetug (ACU193)

  Tmax (Time of the maximum concentration)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), terminal rate

  λz (The observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate time to reach half-life blood levels of sabirnetug (ACU193), half-life

  T1/2 (The observed terminal half-life)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), concentration-time

  AUC168h (Area under the concentration-time curve during a one-week dosing interval)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), last concentration-time

  AUClast (Area under the concentration-time curve from time zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), infinity concentration-time

  AUCinf (Area under the concentration-time curve from time zero extrapolated to infinity)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), extrapolation

  AUCExtrap (%)(The percentage of AUCinf based on extrapolation)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate blood levels of sabirnetug (ACU193), Clast

  Clast (The last quantifiable concentration determined directly from individual concentration-time data)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

• Estimate time to reach last blood levels of sabirnetug (ACU193)

  Tlast (Time of the last quantifiable concentration)

  Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

Study Arms (2)

Arm 1

EXPERIMENTAL

12 participants receive sabirnetug by intravenous infusion

Drug: sabirnetug (ACU193)

Arm 2

EXPERIMENTAL

16 participants receive sabirnetug + rHuPH20 by subcutaneous injection

Combination Product: Sabirnetug + rHuPH20

Interventions

sabirnetug (ACU193) DRUG

sabirnetug by intravenous infusion

Arm 1

Sabirnetug + rHuPH20 COMBINATION_PRODUCT

sabirnetug + rHuPH20 by subcutaneous injection

Arm 2

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily consents to participate in this study and provides written informed consent before the start of any study assessments.
• Male and female participants ≥ 50 years of age.
• Females must be of non-childbearing potential, defined as:
• Postmenopausal females must have had ≥12 months of spontaneous amenorrhea (with documented follicle-stimulating hormone (FSH) ≥40 milli international units (mIU)/mL) or
• Surgically sterile including those who have had a hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 months before the first dose of the study drug.
• Body mass index (BMI) between 18 and 32 kg/m2 (inclusive), and weighs ≥54 kg.
• Screening vital signs (measured after participants have rested in a supine position for a minimum of 5 minutes) within the following ranges: heart rate: 40-100 beats per minute (bpm); systolic blood pressure (BP): 90-150 millimeter of mercury (mmHg); diastolic BP: 50-95 mmHg. Out-of-range vital signs may be repeated once at any time point during the study per Investigator discretion.
• Sperm-producing males in a sexual relationship with females of childbearing potential (FOCBPs) must use adequate contraception (e.g., condom) and must not donate sperm, starting from Screening until 180 days after the last dose of the study drug (See Section 5.3).
• Must be willing to abstain from smoking while confined at the CTU.
• The participant is confirmed to have adequate venous access by study staff.
• Is willing and able to remain in the CTU for the entire duration of each confinement period and return for outpatient visits.

You may not qualify if:

• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.
• Shows signs/symptoms of dementia or has a parent with a known autosomal dominant mutation causing familial AD.
• A clinically significant abnormal finding on the physical exam, medical history, clinical laboratory results or electrocardiogram (ECG), or at Screening. The Investigator may repeat clinical laboratory tests once to assess any out-of-range values for clinical significance.
• Participants with a value \>2.5 times the upper limit of normal (ULN) or \<60% the lower limit of normal (LLN) or any other value of concern per the Investigator will be excluded.
• QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval is \>460ms in females, QTcF\>450ms in males and has ECG findings considered normal or not clinically significant by the Investigator or designee at Screening.
• Suicide risk, as determined by meeting any of the following criteria:
• Any suicide attempt or preparatory acts/behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening in the last six months.
• Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening.
• Significant risk of suicide, as judged by the site Investigator.
• Known allergy to biological products or known hypersensitivity to any component of sabirnetug or hyaluronidase, including excipients.
• Use of any experimental agent within 6 months of the first dose of study drug.
• Administration of vaccinations (e.g., SARS-CoV-2 \[COVID-19\], influenza) within 14 days of administration of the study drug.
• Use of any over the counter (OTC) medication, nutritional or dietary supplements, homeopathic preparations, herbal remedies such as St. John's Wort Extract, or vitamins within 14 days before the first dose of the study drug until EOS without evaluation and approval by the Investigator.
• Use of any prescription medication, starting from 14 days or 5 half-lives (whichever is longer) prior to the first dose of the study drug until EOS without evaluation and approval by the Investigator.
• Blood or plasma donation within 7 days before the first dose of the study drug until EOS. Blood/plasma donations should not be made for at least 90 days after the last dose of the study drug.

Sponsors & Collaborators

• Acumen Pharmaceuticals: lead

Study Sites (1)

Worldwide Clinical Trials

San Antonio, Texas, 78217, United States

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Eric Siemers, M.D.

  Acumen Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2024
• First Posted: July 22, 2024
• Study Start: June 25, 2024
• Primary Completion: September 17, 2024
• Study Completion: September 17, 2024
• Last Updated: October 18, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)